Čes. slov. farm. 2013, 62(4):159-162
Rare diseases in Italy: analysis of the costs and pharmacotherapy
- 1 Università degli Studi di Camerino, School of Pharmaceutical Sciences and Health Products, Camerino (MC), Italy
- 2 Krajská nemocnice T. Bati, a.s., Lékárna, Czech Republic
- 3 Chieti Hospital, Italy
- 4 Università degli Studi di Camerino, School of Specialization in Hospital Pharmacy, Camerino (MC), Italy
Purpose of this research was to analyse the rare diseases drug supply paths in the Italian region of Campania (Health District 47 of the Local Medical Company Naples 1), with a particular focus on current regulations in this field, and quantify the economic incidence of such pathologies in each quarter of 2007 and 2008. Rare, or orphan, diseases are especially serious and onerous from every point of view. Patients meet significant difficulties in obtaining information and in identifying the most appropriate treatment path within the health care system. Pharmaceutical prescriptions were analysed in order to identify the number of patients for each pathology in each quarter of the years 2007 and 2008, the drugs used, the quantity of each drug, and the costs for treatments. Data show a significant increase of costs during each quarter of the year 2008, as well as from 2007 to 2008. In the absence of specific guidelines for the Campania Region, the Local Medical Company of Naples 1 has established a procedure for patients affected by rare diseases that enables them to receive at no cost products that otherwise would not be distributed for free by the health care system.
Keywords: rare diseases; costs; drug supply; Italy
Received: May 31, 2013; Accepted: June 2, 2013; Published: April 1, 2013 Show citation
References
- BCC Research. Global markets for orphan drugs, report. Wellesley: BCC 2007. http://www.bccresearch.com/report//PHM038B.html (13. 2. 2009)
- Regulation (EC) n. 847/2000 of the Commission of 27 April 2000. Application of the criteria for the designation of orphan medicinal product and definitions of the concepts 'similar medicinal product' and 'clinical superiority'. O.J. L103 28.04.2000: 5-8.
- Drummond M. F., Wilson D. A., Kanavos P., Ubel P., Rovira J. Assessing the economic challenges posed by orphan drugs. Int. J. Technol. Assess. Health. Care 2007; 23, 36-42.
Go to original source... 
Go to PubMed... - McCabe C., Claxton K., Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005; 331, 1016-1019. Go to original source... Go to PubMed...
- Regolamento di istituzione della Rete Nazionale delle Malattie Rare e di esenzione dalla partecipazione al costo delle relative prestazioni sanitarie per circa 350 MR. DM n. 279 del 18 maggio 2001. GURI n. 160 del 12 luglio 2001 (Suppl Ord n. 180/L).
- Bianchi F., Taruscio D. Registro Nazionale Malattie Rare. Epidemiologia di 44 malformazioni congenite rare in Italia. Rome: Istituto Superiore di Sanità 2002; Rapporti ISTISAN 02/36.
- Riforma del Titolo V della Costituzione. Legge Costituzionale 8 ottobre 2001, n. 3. GURI n. 248 del 24 ottobre 2001.